Effect of Alfacalcidol Therapy on the Survival of Chronic Hemodialysis Patients

Therapeutic Apheresis and Dialysis

Volumn 16, Issue 3, 2012, Pages 248-253

  Ogawa, Mariko ^a   Ogawa, Tetsuya ^a   Inoue, Tomoko ^a   Otsuka, Kuniaki ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Alfacalcidol; Hemodialysis; Mineral metabolism; Survival rate; Vitamin D

Indexed keywords

ALBUMIN; ALFACALCIDOL; ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CALCIUM; CHOLESTEROL; CREATININE; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGE; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE PRESSURE; SECONDARY HYPERPARATHYROIDISM; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84861330537     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2012.01061.x     Document Type: Article

References (24)

1. Cuppari L, Garcia Lopes MG, Kamimura MA. Vitamin D biology: from the discovery to its significance in chronic kidney disease. J Ren Nutr 2011;21:113-16.
2. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
3. Bouillon R, Carmelliet G, Verlinden L etal. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008;29:726-76.
4. Barreto DV, Barreto FC, Liabeuf S etal. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1128-35.
5. Ravani P, Malberti F, Tripepi G etal. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009;75:88-95.
6. Wolf M, Shah A, Gutierrez O etal. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007;72:1004-13.
7. Pecovnik-Balon B, Jakopin E, Bevc S etal. Vitamin D as a novel nontraditional risk factor for mortality in hemodialysis patients. Ther Apher Dial 2009;13:268-72.
8. Shoji T, Shinohara K, Kimoto E etal. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D 3 users in a haemodialysis population. Nephrol Dial Transplant 2004;19:179-84.
9. Henley C, Colloton M, Cattley RC etal. 1, 25-dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 2005;20:1370-7.
10. Lopez I, Aguilera-Tejero E, Mendoza FJ etal. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006;17:795-804.
11. Wu J, Garami M, Cheng T etal. 1, 25(OH)2 vitamin D3 and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996;97:1577-88.
12. O'Connell TD, Berry JE, Jarvis AK etal. 1, 25-dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 1997;272(Pt 2):H1751-8.
13. Ogawa T, Ishida H, Akamatsu M etal. Relation of oral 1alpha-hydroxy vitamin D3 to the progression of aortic arch calcification in hemodialysis patients. Heart Vessels 2010;25:1-6.
14. Teng M, Wolf M, Lowrie E etal. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56.
15. Kalantar-Zadeh K, Kuwae N, Regidor DL etal. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-80.
16. Tentori F, Hunt WC, Stidley CA etal. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006;70:1858-65.
17. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J etal. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008;74:1070-8.
18. Jean G, Terrat J-C, Vanel T etal. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant 2008;23:3670-6.
19. Jean G, Souberbielle JC, Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 2009;24:3799-805.
20. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005;289:F8-28.
21. Tangpricha V, Spina C, Yao M etal. Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. J Nutr 2005;135:2350-4.
22. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 2003;89:552-72.
23. Gurlek A, Pittelkow MR, Kumar R. Modulation of growth factor/cytokine synthesis and signaling by 1alpha, 25-dihydroxyvitamin D 3: implications in cell growth and differentiation. Endocr Rev 2002;23:763-86.
24. Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 2005;68:1973-81.